Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression
 rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment
 of patients with a recurrent major depressive episode (MDD).

 Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to
 placebo and to assess plasma concentrations of the active metabolite.
Inclusion Criteria:

 -  patients suffering from a recurrent major depressive episode of at least moderate
 intensity (DSM-IV)

 -  patients have been hospitalized for the treatment of a previous episode, or a previous
 episode required antidepressant treatment(s)at the recommended dose level for at least
 2 months.

 -  the duration of the current episode is of at least six weeks unless the severity of
 symptoms justifies shorter duration.